Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00056173
Status:
COMPLETED
Last Update Posted:
2008-01-07
First Post:
2003-03-06
Brief Title:
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
Sponsor:
Aptose Biosciences Inc
Organization:
Aptose Biosciences Inc
Study Overview
Official Title:
A Phase III Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma mRCC
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase II 43 patient trial will evaluate the efficacy of GTI-2040 an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase RNR mRNA in combination with capecitabine in the setting of advancedmetastatic renal cell carcinoma Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None